# Tesamorelin / CJC-1295 / Ipamorelin Blend

> This blend combines two GHRH analogs, tesamorelin and CJC-1295, with a ghrelin-receptor agonist, ipamorelin, aiming for maximal stimulation of the GH axis. Because tesamorelin and CJC-1295 act at the same receptor, the rationale for combining them centers on differing pharmacokinetics, tesamorelin's shorter action alongside CJC-1295's longer, DAC-extended action, rather than a straightforward additive effect. Evidence for this specific three-peptide combination is limited, and it is discussed primarily in informal research contexts rather than clinical literature. Each individual peptide has its own research base, but the triple combination introduces mechanistic overlap that has not been directly studied. It is not approved for human medical use.

- URL: https://www.lifeconverted.com/peptides/tesamorelin-cjc1295-ipamorelin-blend
- Also known as: Triple GH Blend
- Primary category: GH Blends
- Effectiveness rank: #999 in Growth Hormone Peptides; #999 in GH Releasing Hormones; #3 in GH Blends
- Evidence level: Moderate evidence
- Route: Subcutaneous (Injected subcutaneously, often combined in one syringe; some protocols split dosing across the day given the differing durations of action among the three peptides.)
- Dose range: 1,500-3,200 mcg
- Dose tiers: low 1500 mcg; moderate 2200 mcg; high 3200 mcg
- Half-life: Tesamorelin is reported at roughly 25-40 minutes, CJC-1295 without DAC at roughly 30 minutes (or several days with DAC), and ipamorelin at roughly 2 hours, three distinct profiles that add complexity to dosing timing.
- Timing: ~30 min before bed, empty stomach
- Cycle: 8-12 weeks on, 4-6 weeks off (Because two GHRH analogs act on the same receptor, some researchers question whether combining them adds meaningful benefit over a single GHRH analog paired with a ghrelin-receptor agonist.)
- Storage: Refrigerate after reconstitution (2-8°C); most compounded blends are described as stable for 3-4 weeks.

## Mechanism of action

Tesamorelin and CJC-1295 are both GHRH-receptor agonists, so combining them is proposed by proponents to extend the duration of GHRH-receptor stimulation across the day (short-acting tesamorelin layered with longer-acting CJC-1295) rather than simply doubling receptor activation. Ipamorelin contributes an independent ghrelin-receptor pathway. Overall pulse amplification from the three-peptide combination is theorized based on the individual mechanisms of each component, but has not been directly measured for this specific blend.

## Reported benefits

- Aims to amplify and extend growth-hormone pulse coverage
- Supports body composition research
- Associated with recovery support
- General anti-aging research interest

## Reported side effects

- Water retention
- Injection site irritation
- Headache
- Increased hunger
- Joint or muscle discomfort

## Common protocols

- Maximal GH Stack
- Advanced Body Composition Protocol

## Stacking notes

The mechanistic overlap between tesamorelin and CJC-1295 (both GHRH-receptor agonists) means the added benefit of using both together, versus one plus ipamorelin alone, is not well established.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer